Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7737MR)

This product GTTS-WQ7737MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7737MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15763MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ5322MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ11526MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ4484MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ10506MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ10717MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ14110MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ13470MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRS-343
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW